

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 1. (Currently amended) A method for eliciting an immune response in a
2 subject comprising administering an immunogenically effective amount of a peptide or
3 protein antigen comprising one or more T cell epitope(s) coordinately with a non-viral vector
4 comprising a polynucleotide encoding a T-cell B7 co-stimulatory molecule.

1 2. (Original) The method of claim 1, wherein the peptide or protein
2 antigen comprises a T cell epitope of a tumor antigen or viral antigen.

3-5. (Canceled)

1 6. (Currently amended) A method for eliciting an immune response in a
2 subject comprising administering an immunogenically effective amount of a protein antigen
3 comprising at least one T cell epitope coordinately with a non-viral vector comprising a
4 polynucleotide encoding a T-cell B7 co-stimulatory molecule.

1 7. (Original) The method of claim 2, wherein the viral antigen is selected
2 from a human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus
3 (HCV), herpes simplex virus (HSV) or human papilloma virus (HPV) antigen.

1 8. (Original) The method of claim 7, wherein the peptide antigen
2 comprises at least nine contiguous amino acids of a HPV antigenic protein.

9-10. (Canceled)

1 11. (Currently amended) The method of claim 1, wherein the B7 co-
2 stimulatory molecule is ~~selected from B7-1, B7-2, B7-3, or B7-H, ICAM1, ICAM2, ICAM3,~~
3 ~~LFA1, LFA2 or LFA3.~~

1 12. (Currently amended) The method of claim 11, wherein the B7 co-
2 stimulatory molecule is B7-1.

1 13. (Currently amended) The method of claim 1, wherein the peptide
2 antigen and non-viral vector encoding one or more ~~T-cell~~ B7 co-stimulatory molecules are
3 administered to the subject simultaneously as a mixture in a pharmaceutically acceptable
4 carrier or diluent.

1 14. (Currently amended) The method of claim 1, wherein the peptide
2 antigen and non-viral vector encoding the ~~T-cell~~ B7 co-stimulatory molecule are
3 administered separately to the subject in a sequential vaccination protocol.

1 15. (Currently amended) The method of claim 1, wherein the peptide
2 antigen and non-viral vector encoding the ~~T-cell~~ B7 co-stimulatory molecule are
3 administered to proximal target sites selected from the same, or closely-adjacent, intradermal,
4 subcutaneous, mucosal or intratumoral sites.

1 16. (Original) The method of claim 1, wherein the non-viral vector is
2 selected from a RNA or DNA vector.

1 17. (Original) The method of claim 1, wherein the non-viral vector
2 comprises a naked DNA vector having the polynucleotide encoding the co-stimulatory
3 molecule operably linked to regulatory elements necessary for expression of the co-
4 stimulatory molecule in eukaryotic cells.

18-31. (Canceled)